Safety and effectiveness of ruxolitinib as a salvage therapy in refractory graft-versus-host disease after allogenic stem cell transplantation

Trial Profile

Safety and effectiveness of ruxolitinib as a salvage therapy in refractory graft-versus-host disease after allogenic stem cell transplantation

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Nov 2016

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Graft-versus-host disease
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 14 Nov 2016 New trial record
    • 02 Nov 2016 Results presented at the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top